We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Halozyme Therapeutics Incorporated | NASDAQ:HALO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.52 | 1.32% | 39.82 | 37.50 | 42.69 | 40.74 | 38.88 | 39.56 | 832,175 | 00:59:59 |
From May 2019 to May 2024
By Ben Fox Rubin
Biopharmaceutical company Halozyme Therapeutics Inc. (HALO) has entered into a worldwide collaboration and license agreement with pharmaceuticals company Pfizer Inc. (PFE) to develop and commercialize potential treatments that combine Pfizer and Halozyme products.
Under the terms of the agreement, Halozyme granted Pfizer a worldwide license to develop and commercialize products combining Halozyme's patented recombinant human hyaluronidase enzyme with Pfizer proprietary biologics directed to up to six targets.
Halozyme will receive an initial payment of $8 million and is eligible to receive additional payments totaling up to $507 million upon Pfizer reaching certain milestones. Halozyme is also entitled to royalty payments based on net sales of any licensed products.
Halozyme's shares were halted premarket at $5.52, while Pfizer's were down 1.3% at $25.11 premarket.
Write to Ben Fox Rubin at ben.rubin@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Halozyme Therapeutics Chart |
1 Month Halozyme Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
